Combination Oral Health Care Products Safety Defended By Industry
This article was originally published in The Tan Sheet
Executive Summary
Marketing of combination oral health care products should be permitted in the antigingivitis/antiplaque final monograph, according to the Joint Oral Care Task Group of the Consumer Healthcare Products Association and the Cosmetic, Toiletry and Fragrance Association. The group submitted comments to FDA on the subject Nov. 25
You may also be interested in...
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Combination Oral Health Care Products Lack Sufficient Safety Data – J&J
Johnson & Johnson argues against including combination oral health care products in the OTC antingingivitis/antiplaque monograph in Nov. 25 comments to FDA
Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
The antigingivitis/antiplaque monograph should require that products containing a fixed combination of the essential oils menthol, thymol, methyl salicylate and eucalyptol be tested through both in vitro and in vivo test methods, Pfizer Consumer Healthcare maintains